Skip to main content
SpringerLink
Log in
Book cover

Polypharmazie in der Behandlung psychischer Erkrankungen pp 121–137Cite as

Polypharmazie in der Behandlung von Persönlichkeits- und Verhaltensstörungen

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

7. Literatur

  1. APA (1994) Diagnostisches und Statistisches Manual Psychischer Störungen DSM-IV, dt. Bearbeitung und Einleitung: Saß H, Wittchen HU, Zaudig M (1996). Hogrefe Verlag, Göttingen Bern Toronto Seattle

    Google Scholar 

  2. APA (2001) Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry 158 [Suppl]: 1–52

    Article  Google Scholar 

  3. Benedetti F, Barbini B, Campori E, Colombo C, Smeraldi E (1998) Patterns of mood variation during antidepressant treatment. J Affect Disord 46: 133–139

    Article  Google Scholar 

  4. Berger P, Sachs G, Amering M, Holzinger A, Bankier B, Katschnig H (2004) Personality disorder and social anxiety predict delayed response in drug and behavioural treatment of panic disorder. J Affect Disord 80(1): 75–78

    Article  PubMed  Google Scholar 

  5. Cloninger CR, Svrakic DM, Przybeck TR (1993) A psychobiological model of temperament and character. Arch Gen Psychiatry 50: 975–990

    PubMed  CAS  Google Scholar 

  6. Coccaro EF (1997) Assessment of life history of aggression: development and psychometric characteristics. Psychiatry Res 73: 147–157

    Article  PubMed  CAS  Google Scholar 

  7. Cowdry RW, Gardner DL (1988) Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and trancylpromine. Arch Gen Psychiatry 45(2): 111–119

    PubMed  CAS  Google Scholar 

  8. Dammann G, Walter M (2003) Zur Differenzialdiagnose psychotischer Symptome bei Jugendlichen und jungen Erwachsenen mit Borderline Störungen. Psychiatrische Praxis 30: 304–311

    Article  PubMed  Google Scholar 

  9. Davis M (1997) Neurobiology of fear response: the role of the amygdala. J Neuropsychiatry Clin Neurosci 9(3): 382–402

    PubMed  CAS  Google Scholar 

  10. De la Fuente JM, Lotstra F (1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol (4): 479–486

    Article  PubMed  Google Scholar 

  11. Donegan NH, Sanislow CA, Blumberg HP, Fulbright RK, Lacadie C, Skudlarski P, Gore JC, Olson IR, McGlashan TH, Wexler BE (2003) Amygdala hyperreactivity in borderline personality disorder: implications for emotional dysregulation. Biol Psychiatry 54(11): 1284–1293

    Article  PubMed  Google Scholar 

  12. Frankenburg FR, Zanarini MC (2002) Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 63: 442–446

    PubMed  CAS  Google Scholar 

  13. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361(9358): 653–661

    Article  PubMed  CAS  Google Scholar 

  14. Gloagen V (1998) A meta-analysis of the effects of cognitive therapy in depressed patients. J Affect Disord 49: 59–72

    Article  Google Scholar 

  15. Hamer DH, Greenberg BD, Sabol SZ, Murphy DL (1999) Role of the serotonin transporter gene in temperament and character. J Personality Disord 13(4): 312–328

    CAS  Google Scholar 

  16. Herpertz SC, Dietrich TM, Wenning B, Erberich SG, Krings T, Thron A, Sass H (2001) Evidence of abnormal amygdala functioning in borderline personality disorder: a functional MRI study. Biol Psychiatry 50: 292–298

    Article  PubMed  CAS  Google Scholar 

  17. Herpertz SC, Saß H (2002) Persönlichkeitsstörungen. In: Ahrens S, Schneider W (Hrsg) Lehrbuch für Psychosomatische Medizin. Schattauer Verlag, Stuttgart, S 115–124

    Google Scholar 

  18. Herpertz SC, Saß H (2003) Persönlichkeitsstörungen. Thieme Verlag, Stuttgart New York

    Google Scholar 

  19. Herpertz SC (in Druck) Persönlichkeitsstörungen. In: Holsboer D, Gründer G, Benkert O (Hrsg) Handbuch der Psychopharmakotherapie. Springer, Berlin Heidelberg New York Tokyo

    Google Scholar 

  20. Hollander E, Allen A, Lopez RP, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ (2001) A preliminary double-blind placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 62: 199–203

    Article  PubMed  CAS  Google Scholar 

  21. Kapfhammer HJ (2003) Pharmakotherapie bei Persönlichkeitsstörungen. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme Verlag, Stuttgart New York, S 152–164

    Google Scholar 

  22. Kavoussi RJ et al (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55(4): 137–141

    PubMed  CAS  Google Scholar 

  23. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J (2000) A comparison of nefazodone, the cognitive-behavioral-analysis system of psychotherapy, and their combination fort he treatment of chronic depression. New Engl J Med 342: 1462–1470

    Article  PubMed  CAS  Google Scholar 

  24. Keshavan M, Shad M, Soloff P, Schooler N (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophrenic Res 71(1): 97–101

    Article  Google Scholar 

  25. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64(6): 628–634

    Article  PubMed  CAS  Google Scholar 

  26. Kopp B, Wolff M, Hruska C, Reischies F (2002) Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol. Psychophysiology 39: 459–470

    Article  PubMed  Google Scholar 

  27. Leyton M, Okazawa H, Diksic M, Pars J, Rosa P, Mzengeza S, Youn SN, Blier P, Benkelfat C (2001) Brain Regional alpha-[11c]methyl-L-tryptophan trapping in impulsive subjects with borderline personality disorder. Am J Psychiatry 158: 775–782

    Article  PubMed  CAS  Google Scholar 

  28. Liebowitz MR, Heimberg RG, Hope DA, Schneier FR, Holt CS, Welkowitz LA, Juster HR, Campeas R, Bruch MA, Cloitre M, Fallon B, Klein DF (1999) Cognitivebehavioral group-therapy versus phenelzine in social phobia: long-term outcome. Depression & Anxiety 10: 89–98

    Article  CAS  Google Scholar 

  29. Markovitz PJ (1991) Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 148(8): 1064–1067

    PubMed  CAS  Google Scholar 

  30. Norra C, Mrazek M, Tuchtenhagen F, Gobbele R, Buchner H, Sass H, Herpertz SC (2003) Enhanced intensity dependenceas a marker of low serotonergic neurotransmission in borderline personality disorder. J Psychiatric Res 37: 23–33

    Article  Google Scholar 

  31. Pinto OC, Akiskal HS (1998) Lamotrigine as a promising approach to borderline personality disorder: an open case series without concurrent DSM-IV major mood disorder. J Affect Dis 51: 333–343

    Article  PubMed  CAS  Google Scholar 

  32. Reynolds CF et al (1999) Nortriptyline and interpersonal psychotherapy as maintainance therapies for recurrent major depression: a randomized controlled trial inpatients older than 59 years. JAMA 281: 39–45

    Article  PubMed  CAS  Google Scholar 

  33. Rinne T, van den Brink W, Wouters L, van Dyck R (2002) SSRI-Treatment of Borderline-Personality Disorder. A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 159(12): 2048–2054

    Article  PubMed  Google Scholar 

  34. Robbins TW, Everitt BJ (1996) Neurobehavioural mechanism of reward and motivation. Curr Opin Neurobiol 6(2): 228–236

    Article  PubMed  CAS  Google Scholar 

  35. Rocca P, Marchiaro L, Cocuzza E, Bogetto F (2002) Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 62: 241–244

    Google Scholar 

  36. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E (1995) Effect of fluoxetine on anger in symptomatic volounteers with borderline personality disorder. J Clin Psychopharmacol 15: 23–29

    Article  PubMed  CAS  Google Scholar 

  37. Schneier FR, Gortz D, Campeas R, Fallon B, Marshall R, Liebovitz MR(1998) Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172: 70–77

    PubMed  CAS  Google Scholar 

  38. Shea MT, Stout R, Gunderson J, Morey LC, Grilo CM, McGlashan T, Skodol AE, Dolan-Sewell R, Dyck I, Zanarini MC, Keller MB (2002) Short-term diagnostic stability of schizotypal, borderline, avoidant, and obsessive-compulsive personality disorders. Am J Psychiatry 159(12): 2036–2041

    Article  PubMed  Google Scholar 

  39. Siever LJ, Davis KL (1991) A psychobiological perspective on the personality disorders. Am J Psychiatry 148: 1647–1658

    PubMed  CAS  Google Scholar 

  40. Soloff PH, Meltzer CC, Greer PJ, Constantine D, Kelly TM (2000) A fenfluramine-activated FDG-PET study of borderline personality disorder. Biol Psychiatry 47: 540–547

    Article  PubMed  CAS  Google Scholar 

  41. Soloff PH, Kelly TM, Strotmeyer SI et al (2003) Impulsivity, gender, and response to fenfluramine challenge in borderline personality disorder. Psychiatry Res 119: 11–24

    Article  PubMed  CAS  Google Scholar 

  42. Stein DJ, Versiani M, Hair T, Kumar R (2002) Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 59: 1111–1118

    Article  PubMed  CAS  Google Scholar 

  43. Steinberg BJ (1995) The cholinergic and noradrenergic neurotransmitter systems affective instability in borderline personality disorder. In: Biological and neurobehavioral studies in borderline personality disorder. American Psychiatry Press, Washington DC, p 41–59

    Google Scholar 

  44. Torgersen S, Kringlen E, Cramer V (2001) The prevalence of personality disorders in a community sample. Arch Gen Psychiatry 58: 590–596

    Article  PubMed  CAS  Google Scholar 

  45. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebovitz MR, Amre R (1992) Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161: 353–360

    Article  PubMed  CAS  Google Scholar 

  46. Wälte D (2003) Selbstunsichere Persönlichkeitsstörung. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme Verlag, Stuttgart New York, S 117–131

    Google Scholar 

  47. WHO Weltgesundheitsorganisation (1994) Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F) Forschungskriterien. Hans Huber, Bern Göttingen Toronto Seattle

    Google Scholar 

  48. Zanarini MC, Frankenburg FR (2001). Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62: 849–854

    Article  PubMed  CAS  Google Scholar 

  49. Zanarini MC, Frankenburg FR (2003) Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind placebo-controlled pilot study. Am J Psychiatry 160: 167–169

    Article  PubMed  Google Scholar 

  50. Zanarini MC, Frankenburg FR, Vujanovic AA, Hennen J, Reich DB, Silk KR (2004) Axis II comorbidity of borderline personality disorder: description of 6-year course and prediction to time-to-remission. Acta Psychiatr Scand 110(6): 416–420

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universität Rostock, Gehlsheimer Str. 20, 18147, Rostock

    Dr. med. Viola Habermeyer & Dr. med. Elmar Habermeyer

Authors
  1. Dr. med. Viola Habermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Elmar Habermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag/Wien

About this chapter

Cite this chapter

Habermeyer, V., Habermeyer, E. (2006). Polypharmazie in der Behandlung von Persönlichkeits- und Verhaltensstörungen. In: Polypharmazie in der Behandlung psychischer Erkrankungen. Springer, Vienna. https://doi.org/10.1007/3-211-31221-8_5

Download citation

  • DOI: https://doi.org/10.1007/3-211-31221-8_5

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-25286-4

  • Online ISBN: 978-3-211-31221-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation